Table 3.
Treatment outcome (N = 32)
| Outcome | Prostate, n = 22 | Prostate bed, n = 10 |
|---|---|---|
| Acute toxicity of re-EBRT | ||
| Urinary toxicitya | 7 | 1 |
| G1 | 5 | 1 |
| G2 | 2 | 0 |
| Rectal toxicitya | 3 | 1 |
| G1 | 3 | 0 |
| G2 | 0 | 1 |
| Late toxicity of re-EBRT | ||
| Urinary toxicitya | 6 | 1 |
| G1 | 6 | 0 |
| G2 | 0 | 1 |
| Not available (two patients)b | ||
| Rectal toxicitya | 4 | 1 |
| G1 | 4 | 1 |
| Not available (two patients)b | ||
| Status at the last observation (September 2014) | ||
| No evidence of disease | 13 |
|
| Alive with disease | 15 |
|
| Biochemical relapse | 3 |
|
| Clinical local relapse | 4 |
|
| Clinical locoregional relapse | 1 |
|
| Clinical metastatic relapse | 7 |
|
| Dead | 4 |
|
| Metastatic disease | 2 |
|
| Other tumour | 1 |
|
| Other cause | 1 | |
re-EBRT, external beam re-irradiation.
a
According to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria.12
b
Death of the patients before late toxicity check-point.